Compounding recalls, warning letters, and board actions, read for you each morning.

FDA Watch reads FDA recall announcements the day they post, the drug recalls that follow, FDA warning letters, FDA’s compounding inspection actions (Form 483s and untitled letters), changes to FDA’s drug shortage list, and California Board of Pharmacy actions, then emails you only what touches compounding — scored by severity and explained in plain English. No ingredient list to build or maintain.

Start my free 14-day trial See how it works

No charge for 14 days · No watchlist needed

Powered by official public data: FDA recall announcements, openFDA drug recalls, FDA warning letters, FDA’s compounding inspections page (Form 483s, untitled letters), FDA’s drug shortage list, and California Board of Pharmacy accusations and disciplinary actions against compounding licensees.

An industry feed, not a keyword list.

Compounding risk doesn’t fit in a list of ingredients. It’s sterility and endotoxin failures, GLP-1 enforcement, and what regulators do to pharmacies like yours. FDA Watch starts from a compounding profile, so you’re covered on day one.

We start from the compounding profile
503A and 503B, outsourcing facilities, sterile compounding, GLP-1s — built in. Add your own APIs or suppliers if you want them flagged too.
AI reads every record
Each morning we pull new FDA recall announcements, drug recalls, warning letters, 483s, shortage list changes, and board actions, and judge whether each one matters to a compounder — not keyword matches.
You get only what matters
A short email with what happened, why it matters to a compounder, and a severity flag. A board accusation is labelled as an allegation, not a finding. Quiet days mean a quiet inbox.

FDA already emails recalls for free. Here’s what it doesn’t do.

FDA’s alerts are official and free, but they’re built around topics and keywords, not around a compounding pharmacy. This is the difference.

	FDA’s free email alerts	FDA Watch
What gets matched	A topic, or the exact keywords you enter.	A compounding profile, built in. No list to build or maintain.
One recall	Can reach you twice: the announcement email, then again in the Enforcement Report.	When the announcement and the recall record name the same firm and product, you get one alert.
Warning letters	Updates by topic, with no filter for compounding.	Each letter that touches compounding.
483s & inspection actions	Posted on one web page, with no email or RSS feed.	Each 483 and untitled letter at a 503A or 503B facility, also listed publicly at /compounding/actions.
Drug shortages	A separate shortage alert subscription.	A drug added to FDA’s shortage list, or a shortage resolved, in the same digest.
State boards	Not covered.	California Board of Pharmacy accusations and disciplinary actions against compounding licensees.
Your inbox	A separate subscription for each feed.	One morning digest. Quiet days stay quiet.
Price	Free.	$49/mo founding rate, after 14 days free.

FDA Watch is independent and not affiliated with the FDA. FDA’s alerts as described on fda.gov, October 2026.

This is the whole product.

The morning email, exactly as it arrives: most severe first, each item explained for a compounder.

PublicRadar

FDA Watch for CompoundingThis morning

3 items touched compounding today.

1 high · 2 medium · most severe first

High

Tamsin Ridge Compounding Pharmacy announces recall of Glutathione Injection

Tamsin Ridge Compounding Pharmacy announced a recall of Glutathione Injection 200 mg/mL multi-dose vials. Reason given: potential elevated endotoxin levels. Product type: Drugs.

Why it matters to you. A 503A pharmacy recalling a sterile compounded injectable for endotoxin — a product and failure mode many compounders share.

Medium

FDA warning letter to Cedarline Outsourcing, LLC

The FDA issued a warning letter to Cedarline Outsourcing, LLC. Subject: CGMP/Finished Pharmaceuticals/Adulterated.

Why it matters to you. A 503B outsourcing facility cited for CGMP — the kind of finding that signals where inspectors are looking.

Medium

California board accuses Marrow Lane Sterile Pharmacy

The California State Board of Pharmacy filed an accusation against Marrow Lane Sterile Pharmacy (Licensed Sterile Compounding). An accusation is an allegation, not a finding; the case is pending.

Why it matters to you. A sterile compounding licensee facing board action in a state where many compounders hold licenses.

Sample alert. Companies, people, and figures are illustrative.

Cheaper than one afternoon of a recall fire-drill.

One plan, everything included. Start free for 14 days. Built for 503A pharmacies, 503B outsourcing facilities, and the consultants and quality teams who support them.

Founding rate

First 10 customers

$49/mo

Locked for life — the first 10 customers
No watchlist needed: the compounding profile is built in
Recall announcements the day FDA posts them, plus drug recalls
FDA warning letters + California Board of Pharmacy actions
Form 483s + drug shortage list changes
Daily email digest + optional Slack
AI severity scoring + plain-English brief

Claim founding rate

Standard

After the founding cohort

$99/mo

The regular price after the founding cohort
No watchlist needed: the compounding profile is built in
Recall announcements the day FDA posts them, plus drug recalls
FDA warning letters + California Board of Pharmacy actions
Form 483s + drug shortage list changes
Daily email digest + optional Slack
AI severity scoring + plain-English brief

Start free trial

Just your work email. The compounding profile is built in; add anything else you want flagged, or leave it blank.

FDA Watch surfaces publicly available FDA and state board records for informational purposes only. Recalls, warning letters, and board actions are records, not adjudicated findings; a board accusation is an allegation, and a Form 483 lists inspection observations, not a final finding of violation. This is not legal, medical, or regulatory advice — verify against the primary source before acting.